| Patient ID |
Mutations |
Treatment1 |
Treatment2 |
| 6652 |
K14V-I15V-D60E |
SQV |
IDV |
| 6665 |
L10I-K14R-L63P-A71V-G73S-V77I-L90M-I93L |
SQV |
IDV |
| 6670 |
L10I-G16E-P39T-G48V-I54V-D60E-L63P-A71T-V77I-L90M |
SQV |
IDV |
| 6671 |
L10I-I62V-L63P-G73S-V77I-L90M |
SQV |
IDV |
| 6674 |
N37D-Q58E-L63S-A71T-I72T-V77I |
SQV |
IDV |
| 6678 |
K43R-L63P-A71T-I93L |
SQV |
IDV |
| 6685 |
L10I-K14R-L19I-E35G-G48V-F53L-L63A-A71V-I72V-T74S-V77I-V82A |
SQV |
IDV |
| 6686 |
L10I-K20R-E35D-M36I-I50V-D60E-I62V-L63P-A71V-I72T-G73S-L90M-I93L |
SQV |
IDV |
| 6687 |
I13V-I15V-L63A-I72M |
SQV |
IDV |
| 6689 |
I15V-E35D-M36I-N37A-I62V-L63P-G73S-I85V-L90M |
SQV |
IDV |
| 6691 |
E35D-N37D-L63P-A71I-L90M-I93L |
SQV |
IDV |
| 6693 |
T12S-I13V-K14R-G16E-E35D-N37A-L63Q-I64V |
SQV |
IDV |
| 6696 |
I15V-P39T-A71T-L89P-L90M |
SQV |
IDV |
| 6706 |
N37S-L63R-K70V-V77I-I93V |
SQV |
IDV |
| 19255 |
M36I-L63P |
IDV |
NFV |
*Saquinavir (SQV) critical substitutions: red color
SQV additional substitutions: green color
**Indinavir (IDV) critical substitutions: pink color
IDV additional substitutions: yellow color
_ Important residues for drug binding and stability: Asp25, Gly 27, Asp29, Asp30, Gly48, Ile50 |
| Table 6: Residue mutations observed in the 15 patients colored according to their known effect on Saquinavir* and Indinavir** resistance. The analysis is focused
on the catalytic residues important residues for drug binding and stability (Asp25, Gly 27, Asp29, Asp30, Gly48, Ile50), the residues of the active site (Asp25-Thr26-Gly27),
and the residues provoking specific substitutions (see Table, Supplemental Digital Content 3, which shows the HIV-1 mutations that confer resistance to the main protease
inhibitors). |
